186 related articles for article (PubMed ID: 18648365)
1. PRAME expression and clinical outcome of breast cancer.
Epping MT; Hart AA; Glas AM; Krijgsman O; Bernards R
Br J Cancer; 2008 Aug; 99(3):398-403. PubMed ID: 18648365
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and prognostic and predictive relevance of PRAME in breast cancer.
Doolan P; Clynes M; Kennedy S; Mehta JP; Crown J; O'Driscoll L
Breast Cancer Res Treat; 2008 May; 109(2):359-65. PubMed ID: 17624586
[TBL] [Abstract][Full Text] [Related]
3. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
4. Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma.
Kawano R; Karube K; Kikuchi M; Takeshita M; Tamura K; Uike N; Eto T; Ohshima K; Suzumiya J
J Clin Exp Hematop; 2009 May; 49(1):1-7. PubMed ID: 19474511
[TBL] [Abstract][Full Text] [Related]
5. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
[TBL] [Abstract][Full Text] [Related]
6. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
[TBL] [Abstract][Full Text] [Related]
7. Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo.
Tajeddine N; Louis M; Vermylen C; Gala JL; Tombal B; Gailly P
Leuk Lymphoma; 2008 Jun; 49(6):1123-31. PubMed ID: 18452107
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis.
Li J; Yin J; Zhong J; Yang Z; Tang A; Li S
Biomed Res Int; 2020; 2020():8828579. PubMed ID: 33381588
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients.
Kumar N; Singh MK; Singh L; Lomi N; Meel R; Pushker N; Sen S; Kashyap S
Hum Cell; 2023 Jan; 36(1):342-352. PubMed ID: 36282437
[TBL] [Abstract][Full Text] [Related]
10. PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer.
Baba H; Kanda M; Sawaki K; Umeda S; Miwa T; Shimizu D; Tanaka C; Kobayashi D; Fujiwara M; Kodera Y; Fujii T
Ann Surg Oncol; 2020 Jun; 27(6):2071-2080. PubMed ID: 31659640
[TBL] [Abstract][Full Text] [Related]
11. Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential.
Naik A; Thomas R; Al-Khadairi G; Bacha R; Hendrickx W; Decock J
J Cell Mol Med; 2021 Nov; 25(22):10376-10388. PubMed ID: 34612587
[TBL] [Abstract][Full Text] [Related]
12. Molecular and clinicopathological implications of PRAME expression in adult glioma.
Le MK; Vuong HG; Dunn IF; Kondo T
PLoS One; 2023; 18(10):e0290542. PubMed ID: 37796789
[TBL] [Abstract][Full Text] [Related]
13. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
14. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
Field MG; Decatur CL; Kurtenbach S; Gezgin G; van der Velden PA; Jager MJ; Kozak KN; Harbour JW
Clin Cancer Res; 2016 Mar; 22(5):1234-42. PubMed ID: 26933176
[TBL] [Abstract][Full Text] [Related]
15. PRAME is critical for breast cancer growth and metastasis.
Sun Z; Wu Z; Zhang F; Guo Q; Li L; Li K; Chen H; Zhao J; Song D; Huang Q; Li L; Xiao J
Gene; 2016 Dec; 594(1):160-164. PubMed ID: 27632898
[TBL] [Abstract][Full Text] [Related]
16. PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis.
Abdelmalak CA; Yahya RS; Elghannam DM; El-Khadragy AE; Abd El Messih HM
Clin Lab; 2014; 60(1):55-61. PubMed ID: 24600975
[TBL] [Abstract][Full Text] [Related]
17. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of long noncoding RNA HOTTIP on clinical outcomes in breast cancer.
Yang Y; Qian J; Xiang Y; Chen Y; Qu J
Oncotarget; 2017 Jan; 8(4):6833-6844. PubMed ID: 28036281
[TBL] [Abstract][Full Text] [Related]
20. The effect of preferentially expressed antigen in melanoma (PRAME) expression status on survival in stage II and stage III colon cancer.
Ogul A; Paydas S; Doran F; Erdogan KE; Tohumcuoglu M; Buyuksimsek M; Mirili C; Yetisir AE
J BUON; 2021; 26(3):992-1001. PubMed ID: 34268964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
